In order to target non-redundant immune regulatory pathways, such as those activated by TGFβ and PD-1/PD-L1 or CTLA-4 expression, we proposed combining ICB with isoform-specific TGFβ inhibition in order to improve CD8+ T cell responses and anti-tumor immunity. The gene discussed is TGFB1; the disease is neoplasm.